Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 14/20 | 0.53 |
| ▸ | CNR1 | P21554 | 5/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | GRK6 | P43250 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19121455 | 0.87 | ALDH1A1 (0.47) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL20066465 | 0.87 | CNR2 (0.47) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL12000833 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL4434581 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL12319448 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL10152990 | 0.84 | CNR2 (0.45) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL131813 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL18509211 | 0.82 | CNR2 (0.50) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL9158083 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 | |
| SCHEMBL11107464 | 0.82 | CNR2 (0.50) | ALDH1A1TSHRPSMD14CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024014536-A1 | REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS | 国立研究開発法人産業技術総合研究所 | 2024-01-18 | — | — | WO | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220023270-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090110718-A1 | Derivatives of tiacumicin B as anti-cancer agents | ECHEM HIGHTECH CO., LTD. (TW) | 2009-04-30 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| US-4397931-A | Stabilized organic layered photoconductive device | XEROX CORPORATION (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110718-A1 | Derivatives of tiacumicin B as anti-cancer agents | TIA1, TIAL1, TIAM1 | ALDH1A1 1612/4885TSHR 1617/4885PSMD14 4494/4885 |
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGER1 | ALDH1A1 1095/4885TSHR 1264/4885PSMD14 3373/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | ALDH1A1 3235/4885TSHR 3866/4885PSMD14 3848/4885 |
| US-20220023270-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CLPP, SPOUT1, MRPL21 | ALDH1A1 2700/4885TSHR 4783/4885PSMD14 1637/4885 |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | ESR1, ECE1, ESYT1 | ALDH1A1 722/4885TSHR 3456/4885PSMD14 1484/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ALDH1A1 3524/4885TSHR 1187/4885PSMD14 3750/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | ALDH1A1 72/4885TSHR 935/4885PSMD14 4334/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | ALDH1A1 2317/4885TSHR 2205/4885PSMD14 131/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885TSHR 3007/4885PSMD14 3408/4885 |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | ALDH1A1 1108/4885TSHR 4050/4885PSMD14 4732/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | ALDH1A1 2289/4885TSHR 508/4885PSMD14 3065/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | ALDH1A1 4573/4885TSHR 654/4885PSMD14 3656/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | ALDH1A1 1655/4885TSHR 3938/4885PSMD14 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.